• Something wrong with this record ?

Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites

G. Krumpl, I. Ulč, M. Trebs, P. Kadlecová, J. Hodisch, G. Maurer, B. Husch,

. 2018 ; 71 (3) : 137-146.

Language English Country United States

Document type Comparative Study, Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc19013026

The pharmacokinetics, pharmacodynamics, safety, and tolerability of long-term administration of esmolol and landiolol, a new fast-acting cardioselective β-blocker, were compared for the first time in Caucasian subjects in a prospective clinical trial. Twelve healthy volunteers received landiolol and esmolol by continuous infusion for 24 hours in a randomized crossover study using a dose-escalation regimen. Blood concentrations of drugs and metabolites, heart rate, blood pressure, ECG parameters, and tolerability were observed for 30 hours and compared. Drug blood concentrations and areas under the curve were dose-proportional. The half life of landiolol (4.5 minutes) was significantly shorter than that of esmolol (6.9 minutes). Volume of distribution and total clearance were lower for landiolol. Heart rate reduction was faster and more pronounced with landiolol and retained throughout the administration period; effects on blood pressure were not different. Landiolol turned out to be superior to esmolol with respect to pharmacokinetic and pharmacodynamic profile and local tolerability.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013026
003      
CZ-PrNML
005      
20200221074532.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FJC.0000000000000554 $2 doi
035    __
$a (PubMed)29112591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krumpl, Günther $u MRN Medical Research Network GmbH, Vienna, Austria.
245    10
$a Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites / $c G. Krumpl, I. Ulč, M. Trebs, P. Kadlecová, J. Hodisch, G. Maurer, B. Husch,
520    9_
$a The pharmacokinetics, pharmacodynamics, safety, and tolerability of long-term administration of esmolol and landiolol, a new fast-acting cardioselective β-blocker, were compared for the first time in Caucasian subjects in a prospective clinical trial. Twelve healthy volunteers received landiolol and esmolol by continuous infusion for 24 hours in a randomized crossover study using a dose-escalation regimen. Blood concentrations of drugs and metabolites, heart rate, blood pressure, ECG parameters, and tolerability were observed for 30 hours and compared. Drug blood concentrations and areas under the curve were dose-proportional. The half life of landiolol (4.5 minutes) was significantly shorter than that of esmolol (6.9 minutes). Volume of distribution and total clearance were lower for landiolol. Heart rate reduction was faster and more pronounced with landiolol and retained throughout the administration period; effects on blood pressure were not different. Landiolol turned out to be superior to esmolol with respect to pharmacokinetic and pharmacodynamic profile and local tolerability.
650    _2
$a mladiství $7 D000293
650    _2
$a antagonisté beta-1-adrenergních receptorů $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D058671
650    _2
$a beta blokátory $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000319
650    _2
$a dospělí $7 D000328
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a běloši $7 D044465
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a morfoliny $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D009025
650    _2
$a propanolaminy $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D011412
650    _2
$a prospektivní studie $7 D011446
650    _2
$a terapeutická ekvivalence $7 D013810
650    _2
$a močovina $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x farmakokinetika $7 D014508
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ulč, Ivan, $d 1955- $7 xx0245156 $u Center for Pharmacology and Analysis (CEPHA) s.r.o., Plzeň, Czech Republic.
700    1_
$a Trebs, Michaela $u AOP Orphan Pharmaceuticals AG, Vienna, Austria.
700    1_
$a Kadlecová, Pavla $u APROVA s.r.o., Brno, Czech Republic.
700    1_
$a Hodisch, Juri $u AOP Orphan Pharmaceuticals AG, Vienna, Austria.
700    1_
$a Maurer, Gabriele $u AOP Orphan Pharmaceuticals AG, Vienna, Austria.
700    1_
$a Husch, Bernhard $u Complex GmbH, Vienna, Austria.
773    0_
$w MED00002571 $t Journal of cardiovascular pharmacology $x 1533-4023 $g Roč. 71, č. 3 (2018), s. 137-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29112591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20200221074937 $b ABA008
999    __
$a ok $b bmc $g 1392336 $s 1051331
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 71 $c 3 $d 137-146 $i 1533-4023 $m Journal of cardiovascular pharmacology $n J Cardiovasc Pharmacol $x MED00002571
LZP    __
$a Pubmed-20190405
Back

Find record

Citation metrics

Archiving options